Literature DB >> 32066575

Posterior reversible encephalopathy syndrome associated with the use of chemotherapeutic agents: a rare complication after treatment with vinorelbine.

Ines Gil1, Filipa Serrazina2, Miguel Pinto2, Miguel Viana-Baptista2.   

Abstract

The posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological syndrome characterised by a combination of headache, encephalopathy, seizures and visual disturbances, associated with high-intensity abnormalities on T2-weighted images affecting subcortical white and grey matter of the occipital and parietal lobes. Among other causes, PRES has been associated with the use of several medications including chemotherapeutic agents. Here we report a case of a 65-year-old patient with squamous cell carcinoma of the lung treated with cisplatin/vinorelbine. Following the second administration of vinorelbine, she was admitted to the hospital for a generalised seizure. Blood pressure was just slightly elevated and, except for drowsiness, she had a near-normal neurological examination. MRI corroborated the diagnosis. Vinorelbine-induced PRES has been reported only once in the literature, also in association with cisplatin. Our case underlines the role of vinorelbine and suggests that its association with cisplatin in this setting may enhance the risk of PRES. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  chemotherapy; epilepsy and seizures; radiology; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2020        PMID: 32066575      PMCID: PMC7046420          DOI: 10.1136/bcr-2019-229319

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  32 in total

1.  Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient.

Authors:  Takahiro Maeda; Eiji Kikuchi; Kazuhiro Matsumoto; Satoshi Yazawa; Jun Hagiuda; Akira Miyajima; Ken Nakagawa; Hirokazu Fujiwara; Haruhiko Hoshino; Mototsugu Oya
Journal:  Int J Clin Oncol       Date:  2010-03-30       Impact factor: 3.402

2.  Antiphospholipid syndrome and reversible posterior leukoencephalopathy syndrome.

Authors:  Monica Bandettini di Poggio; Giuseppe Murdaca; Francesco Puppo; Alberto Primavera
Journal:  Semin Arthritis Rheum       Date:  2009-10-31       Impact factor: 5.532

3.  Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.

Authors:  Emil Lou; Scott Turner; Ashley Sumrall; David A Reardon; Annick Desjardins; Katherine B Peters; John H Sampson; Henry S Friedman; James J Vredenburgh
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

4.  Ocular Dysfunctions Presenting in Tacrolimus-Induced Posterior Reversible Encephalopathy Syndrome: A Case Presentation.

Authors:  Cora H Brown; Alexander J Feng; Ernesto Cruz
Journal:  PM R       Date:  2017-09-12       Impact factor: 2.298

5.  [Reversible posterior leukoencephalopathy, severe hypertension, and cocaine abuse].

Authors:  E Rodríguez Gómez; F J Rodríguez Gómez; M J Merino; A Robledo; J M López Domínguez; F Fernández Girón; J González Martínez
Journal:  Nefrologia       Date:  2001 May-Jun       Impact factor: 2.033

Review 6.  Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy-related intracranial effects.

Authors:  Christie M Lincoln; Peter Fata; Susan Sotardi; Michael Pohlen; Tomas Uribe; Jacqueline A Bello
Journal:  Br J Radiol       Date:  2017-11-03       Impact factor: 3.039

Review 7.  The posterior reversible encephalopathy syndrome: what's certain, what's new?

Authors:  C Roth; A Ferbert
Journal:  Pract Neurol       Date:  2011-06

8.  Neurological variability in chemotherapy-induced posterior reversible encephalopathy syndrome associated with thrombotic microangiopathy: Case reports and literature review.

Authors:  Chen Makranz; Salome Khutsurauli; Yosef Kalish; Ruth Eliahou; Luna Kadouri; John Moshe Gomori; Alexander Lossos
Journal:  Mol Clin Oncol       Date:  2017-11-02

9.  Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome.

Authors:  W S Bartynski; J F Boardman
Journal:  AJNR Am J Neuroradiol       Date:  2007-08       Impact factor: 3.825

10.  Extended use dexamethasone-associated posterior reversible encephalopathy syndrome with cisplatin-based chemotherapy.

Authors:  MyChau T Nguyen; Irim Y Virk; Lita Chew; J Lee Villano
Journal:  J Clin Neurosci       Date:  2009-10-02       Impact factor: 1.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.